Curis

Curis, Inc. engages in the development and commercialization of drug candidates for the treatment of human cancers. Its pipeline includes CUDC-907, CA-4948, CA-170 and CA-327. The CUDC-907 pipeline is an orally available small molecule inhibitor of HDAC and PI3K enzymes. The CA-170 pipeline is an also an orally-available small molecule antagonist of PD-L1 and VISTA immune checkpoints. The company was founded on February 14, 2000 and is headquartered in Lexington, MA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Curis reports reduced losses, positive clinical data drive growth prospects

Curis demonstrated improved financial performance, strengthened by successful fundraising and promising clinical data, positioning the company for future growth.
While facing challenges in regulatory processes and balancing expenses, Curis remains focused on innovation and market opportunities to drive value creation.
Investors should monitor Curis' upcoming presentations and regulatory developments closely, as positive outcomes could significantly impact the company's trajectory.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Initial TakeAim Lymphoma combination data shows anti-cancer activity, including 1 complete response and 2 partial responses, in heavily pretreated patients including those with prior ibrutinib use LEXINGTON, Mass. , May 12, 2022 /PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, today announced that multiple abstracts have been accepted for presentation at the upcoming European Hematology Association 2022 Hybrid Congress (EHA), which will be held virtually and in-person in Vienna on June 9-12, 2022.

Curis Announces Abstracts Accepted for Presentation at the European Hematology Association 2022 Congress (EHA)

Curis, Inc. (NASDAQ:CRIS ) Q1 2022 Earnings Conference Call May 5, 2022 4:30 PM ET Company Participants Craig West - Vice President of Investor Relations and Corporate Communications Jim Dentzer - President and Chief Executive Officer Bill Steinkrauss - Chief Financial Officer and Chief Administrative Officer Bob Martell - Head of R&D Conference Call Participants Soumit Roy - Jones Research Yale Jen - Laidlaw and Company Operator 00:07 Good afternoon everyone and welcome to Curis' First Quarter 2022 Earnings Conference Call. [Operator Instructions] Please also note, today's event is being recorded.

Curis Inc.'s (CRIS) CEO Jim Dentzer on Q1 2022 Results - Earnings Call Transcript

Strong balance sheet with $120.7 million in cash and investments at March 31, 2022; no change to cash guidance: cash runway into 2024 Potential opportunity for emavusertib in pancreatic cancer highlighted in a publication from Washington University in St. Louis Management to host conference call today at 4:30 p.m. ET LEXINGTON, Mass.

Curis Reports First Quarter 2022 Financial Results and Business Update

Curis (CRIS) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.

Down 31.3% in 4 Weeks, Here's Why You Should You Buy the Dip in Curis (CRIS)

LEXINGTON, Mass. , April 28, 2022 /PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, today announced that the Company will release its first quarter 2022 financial results on Thursday, May 5, 2022, after the close of U.S. markets.

Curis to Release First Quarter 2022 Financial Results and Hold Conference Call on May 5, 2022

NEW YORK , April 25, 2022 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Curis, Inc. ("Curis" or the "Company") (NASDAQ: CRIS). Such investors are advised to contact Robert S.

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Curis, Inc. - CRIS

The FDA places a partial clinical hold on Curis' (CRIS) phase I/II TakeAim lymphoma study investigating emavusertib in patients with B-cell malignancies. Shares fall.

Curis (CRIS) Down on FDA Partial Clinical Hold on Lymphoma Study

The FDA has placed a partial clinical hold on Curis Inc's (NASDAQ: CRIS) TakeAim Lymphoma study. The TakeAim Lymphoma study is a Phase 1/2 open-label dose-escalating clinical trial investigating emavusertib in patients with B-cell malignancies.

After Leukemia Trial, FDA Puts Partial Hold On Curis' Lymphoma Study

Curis voluntarily paused enrollment in this study earlier LEXINGTON, Mass. , April 11, 2022 /PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, today announced that the U.S. Food and Drug Administration (FDA) has placed a partial clinical hold on the Company's TakeAim Lymphoma study (NCT03328078).

Curis Announces FDA Partial Clinical Hold for TakeAim Lymphoma Study of Emavusertib (CA-4948)

LEXINGTON, Mass. , April 5, 2022 /PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, today announced that James Dentzer, President and Chief Executive Officer of Curis, will present a company overview at the 21st Annual Needham Virtual Healthcare Conference.

Curis to Present at 21st Annual Needham Virtual Healthcare Conference

The FDA has placed a partial clinical hold on Curis Inc's (NASDAQ: CRIS) TakeAim Leukemia Phase 1/2a study in relapsed or refractory (R/R) acute myeloid leukemia (AML) or high-risk myelodysplastic syndrome (MDS). The TakeAim Leukemia study is evaluating emavusertib (CA-4948.

Curis Plummets To 52-Week Low After FDA Clinical Hold On Blood Cancer Trial

LEXINGTON, Mass. , April 4, 2022 /PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, today announced that the U.S. Food and Drug Administration (FDA) has placed a partial clinical hold on the Company's TakeAim Leukemia Phase 1/2a study (NCT04278768).

Curis Announces FDA Partial Clinical Hold for TakeAim Leukemia Study of Emavusertib (CA-4948)

LEXINGTON, Mass., March 7, 2022 /PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, today announced that a manuscript has been published in the peer-reviewed journal Gastroenterology, authored by Curis collaborators at Washington University School of Medicine in St. Louis, on the role of IRAK4 in pancreatic ductal adenocarcinoma (PDAC) and the preclinical efficacy of emavusertib (CA-4948), a novel, small molecule IRAK4 inhibitor, in combination with checkpoint immunotherapy.

Curis Announces Gastroenterology Publication of Encouraging Preclinical Data of Emavusertib in Pancreatic Cancers

Curis Inc. (CRIS) CEO James Dentzer on Q4 2021 Results - Earnings Call Transcript

Curis (CRIS) delivered earnings and revenue surprises of -15.38% and 3.26%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

Curis (CRIS) Reports Q4 Loss, Tops Revenue Estimates

LEXINGTON, Mass., Feb. 24, 2022 /PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, today reported its financial results for the fourth quarter ended December 31, 2021.

Curis Reports Fourth Quarter and Year End 2021 Financial Results

LEXINGTON, Mass., Feb. 17, 2022 /PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, today announced that the Company will release its fourth quarter 2021 financial results on Thursday, February 24, 2022, after the close of U.S. markets.

Curis to Release Fourth Quarter 2021 Financial Results and Hold Conference Call on February 24, 2022

LEXINGTON, Mass., Jan. 20, 2022 /PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, today announced that James Dentzer, President and Chief Executive Officer, will participate in the following upcoming conferences: B.

Curis to Present at Upcoming Healthcare Conferences

Investors need to pay close attention to Curis (CRIS) stock based on the movements in the options market lately.

Is the Options Market Predicting a Spike in Curis (CRIS) Stock?

LEXINGTON, Mass., Jan. 6, 2022 /PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, today announced positive updated clinical data from the ongoing open label Phase 1/2 dose escalation and expansion study of CA-4948, a novel, small molecule IRAK-4 inhibitor, as a monotherapy in patients with relapsed or refractory (R/R) acute myeloid leukemia (AML) or high risk myelodysplastic syndromes (MDS) as well as initial safety, pharmacokinetic and pharmacodynamic data from the Phase 1 dose escalation study of CI-8993, a monoclonal antibody targeting VISTA for patients with R/R solid tumors.

Curis Announces Updated Data with Additional Encouraging Clinical Activity in Phase 1/2 Study of CA-4948 Monotherapy in Targeted Patients with Relapsed or Refractory AML and MDS; and Initial Clinical Data from Phase 1 Study of CI-8993 in Patients with Rel

LEXINGTON, Mass., Jan. 3, 2022 /PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, today announced the appointment of three new executives to its management team.

Curis Adds Three New Executives to Management Team Strengthening Medical Affairs, Clinical Development and Clinical Operations

LEXINGTON, Mass., Jan. 3, 2022 /PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, today announced that James Dentzer, President and Chief Executive Officer of Curis, will present at the H.C.

Curis to Present at H.C. Wainwright BioConnect Conference

iShares Nasdaq Biotechnology ETF

LEXINGTON, Mass., Dec. 15, 2021 /PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, today announced that it has been selected for addition to the Nasdaq Biotechnology Index (NASDAQ: NBI) and the iShares Biotechnology ETF (NYSE: IBB).

Curis to be Added to the Nasdaq Biotechnology Index and the iShares Biotechnology ETF

Curis (CRIS) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Curis (CRIS) Moves to Buy: Rationale Behind the Upgrade

LEXINGTON, Mass., Dec. 6, 2021  /PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, today announced the appointment of John A.

News for Curis Stock (CRIS)